N Nanobiotix
N
Atvērts
29.94 -1.84
Pārskats
Akcijas cenas izmaiņa
24h
Min
29.7
Max
30.5
Ienākumi | -13M -19M |
|---|---|
Pārdošana | -24M 3M |
Peļņas marža | -618.236 |
Darbinieki | 100 |
EBITDA | -14M -13M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +81.4% upside |
Nākamie ieņēmumi | 2026. g. 23. jūn. |
|---|
Tirgus kapitalizācija | 277M 1.6B |
|---|---|
Iepriekšējā atvēršanas cena | 31.78 |
Iepriekšējā slēgšanas cena | 29.94 |
Nanobiotix Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
